BC-05

• Description :

  BC-05 is an orally active and potent inhibitor of CD13 and proteasome. BC-05 has an IC50 value of 0.13 μM for human CD13 and an IC50 value of 1.39 μM for the 20S proteasome. BC-05 can be used in multiple myeloma research[1].

• UNSPSC :

  12352005

• Target :

  Proteasome

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bc-05.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(N[C@@H](CC(C)C)B1OC(C(CC(O)=O)(CC(O)=O)O1)=O)[C@@H](O)[C@H](N)CC2=CC=CC=C2

• Molecular Formula :

  C21H29BN2O9

• Molecular Weight :

  464.27

• References & Citations :

  [1]Zhang J, et al. Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer. Molecules. 2023 Aug 30;28 (17) :6343.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2260717-73-3]